Melatonin
Melatonin, licence 80074183: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Wing Quon NHP Production Inc.
- NPN or DIN-HM
- 80074183
- Status
- Active licence
- Licence date
- 2 December 2016
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]acétamide Source : Mélatonine | 5.0 milligramme | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1.0 Comprimé | 1.0 Tous les jours |
Uses authorised in Canada
Helps increase total sleep time aspect of sleep quality in people suffering from sleep restrictions or altered sleep schedule, e.g. shift-work and jet lag. Helps to reduce the time it takes to fall asleep in people with delayed sleep phase syndrome.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use if you have a hormonal disorder, diabetes, liver or kidney disease, cerebral palsy, seizure disorders, migraine, depression and/or hypertension or if you are taking blood pressure or sedative/hypnotic medications. If you are taking prescription medications, consult a health care practitioner prior to use. If symptoms persist continuously for more than 4 weeks (chronic insommia) or if pain or other factors appear to be the cause of sleeplessness, consult your health care practitioner. Consumption with alcohol, other medications or natural health products with sedative properties is not recommended. If you are taking one of the following medications, consult a health care practitioner prior to use: anticoagulant, anticonvulsant, blood pressure medications, immunosuppressive medications, sedative, hypnotic or ppsychotropic medications, or steroids. If you haveone of the following conditions, consult a health care practitioner prior to use: asthma, cardiovascular disease, hypoglycaemia, immune system disease. Mild gastrointestinal symptoms (nausea, vomiting, or cramping) have been known to occur in which case, discontinue use. Rare allergic reactions have been known to occur in which case, discontinue use.
- Contre-indications
Do not use product during pregnancy and breastfeeding. Do not use if you are taking immunosuppressive drugs. Do not drive or use machinery for 5 hours after taking melatonin.
Source
Official Health Canada record, licence 80074183
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.